Table 3.

Clinical outcomes as a function of high- vs. low-CTRA gene expression

A	B	C	D
Outcome	High CTRA expression	Low CTRA expression	p-value
	[% of cohort, 95% CI]	[% of cohort, 95% CI]
	N=39	N=39
Neutrophil recovery @ 100 days	92 (83–98)	85 (72–94)	0.27
aGVHD @ 100 days	49 (33–64)	62 (46–76)	0.25
cGVHD			0.08
@ 1 year	30 (16–45)	35 (21–51)	0.61
@ 3 years	30 (16–45)	47 (31–63)	0.13
TRM			0.61
@ 100 days	33 (20–49)	23 (12–38)	0.33
@ 1 year	44 (29–59)	40 (25–56)	0.74
@ 3 years	44 (29–59)	44 (28–60)	0.98
Relapse			0.04
@ 1 year	18 (8–31)	8 (2–19)	0.2
@ 3 years	31 (17–46)	11 (3–23)	0.04
LFS			0.04
@ 1 year	38 (24–54)	52 (36–68)	0.23
@ 3 years	26 (13–41)	45 (29–62)	0.09
OS			0.09
@ 1 year	44 (29–59)	54 (38–69)	0.36
@ 3 years	25 (12–42)	47 (31–63)	0.14

CTRA, conserved transcriptional response to adversity; GVHD, graft-versus-host disease (a=acute, c=chronic); LFS, leukemia-free survival; OS, overall survival; TRM, transplant-related mortality